Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients

[1]  Tomoki Tanaka,et al.  Distribution analysis of hydrogel spacer and evaluation of rectal dose reduction in Japanese prostate cancer patients undergoing stereotactic body radiation therapy , 2021, International Journal of Clinical Oncology.

[2]  Jun Sugawara,et al.  Stereotactic body radiotherapy with a single isocentre for multiple pulmonary metastases , 2020, BJR case reports.

[3]  L. Livi,et al.  Faculty Opinions recommendation of Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. , 2020 .

[4]  K. Tabata,et al.  A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer , 2019, Radiation oncology.

[5]  M. Zelefsky,et al.  Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.

[6]  Pengfei Guo,et al.  A meta-analysis of randomized controlled trials , 2019, Medicine.

[7]  A. Kishan,et al.  Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer , 2019, JAMA network open.

[8]  K. Hoffman,et al.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Brachman,et al.  Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. , 2018, International journal of radiation oncology, biology, physics.

[10]  K. Hoffman,et al.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. , 2018, The Journal of urology.

[11]  Misop Han,et al.  Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. , 2017, Urology.

[12]  A. Katz.  Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis , 2017, Cureus.

[13]  P. Cheung,et al.  Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose? , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  I. Hsu,et al.  Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer. , 2017, Practical radiation oncology.

[15]  A. Kishan,et al.  Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer. , 2017, International journal of radiation oncology, biology, physics.

[16]  É. Vigneault,et al.  Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  A. D'Amico,et al.  A systematic review of hypofractionation for primary management of prostate cancer. , 2015, European urology.

[18]  Hans T. Chung,et al.  High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  A. Hanlon,et al.  SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines , 2014, Front. Oncol..

[20]  Yair Lotan,et al.  Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. , 2014, International journal of radiation oncology, biology, physics.

[21]  J. Boormans,et al.  P068 Stereotactic body radiotherapy with four fractions for low- and intermediate-risk prostate cancer: Acute and late toxicity , 2013 .

[22]  E. Oermann,et al.  Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience , 2013, Radiation Oncology.

[23]  G. Viani,et al.  Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. , 2009, International journal of radiation oncology, biology, physics.

[24]  Yoshiya Yamada,et al.  Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.

[25]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[26]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[27]  M W Kattan,et al.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.